Michal Tomcik

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6519058/publications.pdf

Version: 2024-02-01

142	12,723	186209	91828
papers	citations	28 h-index	69 g-index

145	145	145	17921
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. Scientific Reports, 2021, 11, 1.	1.6	9,439
2	Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1327-1339.	0.5	794
3	Orphan nuclear receptor NR4A1 regulates transforming growth factor-Î² signaling and fibrosis. Nature Medicine, 2015, 21, 150-158.	15.2	267
4	The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatology, The, 2020, 2, e71-e83.	2.2	182
5	Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis and Rheumatism, 2012, 64, 2724-2733.	6.7	133
6	Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Annals of the Rheumatic Diseases, 2011, 70, 1304-1310.	0.5	116
7	JAKâ€2 as a novel mediator of the profibrotic effects of transforming growth factor Î² in systemic sclerosis. Arthritis and Rheumatism, 2012, 64, 3006-3015.	6.7	115
8	Sirt1 regulates canonical TGF-Î² signalling to control fibroblast activation and tissue fibrosis. Annals of the Rheumatic Diseases, 2016, 75, 226-233.	0.5	115
9	Vitamin D receptor regulates TGF-Î² signalling in systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, e20-e20.	0.5	111
10	Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis and Rheumatism, 2011, 63, 1396-1404.	6.7	107
11	Inhibition of activator protein 1 signaling abrogates transforming growth factor Î²â€“mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis and Rheumatism, 2012, 64, 1642-1652.	6.7	81
12	Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-Î² signalling to prevent fibrosis. Annals of the Rheumatic Diseases, 2014, 73, 1215-1222.	0.5	78
13	Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 1019-1026.	0.5	74
14	Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis and Rheumatism, 2011, 63, 800-809.	6.7	73
15	Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 785-789.	0.5	73
16	The metastasis-associated protein S100A4 promotes the inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid arthritis. Rheumatology, 2014, 53, 1520-1526.	0.9	72
17	Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis and Rheumatism, 2010, 62, 3467-3476.	6.7	67
18	A synthetic PPAR-Î³ agonist triterpenoid ameliorates experimental fibrosis: PPAR-Î³-independent suppression of fibrotic responses. Annals of the Rheumatic Diseases, 2014, 73, 446-454.	0.5	62

#	Article	IF	Citations
19	The transcription factor JunD mediates transforming growth factor Â-induced fibroblast activation and fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 2011, 70, 1320-1326.	0.5	59
20	Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 737-745.	0.5	53
21	Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood, 2012, 120, 2909-2917.	0.6	53
22	S100A4 amplifies TGF-Î² -induced fibroblast activation in systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 1748-1755.	0.5	52
23	Tribbles homologue 3 stimulates canonical TGF-Î² signalling to regulate fibroblast activation and tissue fibrosis. Annals of the Rheumatic Diseases, 2016, 75, 609-616.	0.5	38
24	The metastasis promoting protein S100A4 is increased in idiopathic inflammatory myopathies. Rheumatology, 2011, 50, 1766-1772.	0.9	35
25	Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 72, 1089-1098.	0.5	35
26	Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. Annals of the Rheumatic Diseases, 2012, 71, 1895-1899.	0.5	31
27	Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis. Cytokine, 2012, 58, 165-168.	1.4	29
28	Inhibition of Notch1 promotes hedgehog signalling in a HES1-dependent manner in chondrocytes and exacerbates experimental osteoarthritis. Annals of the Rheumatic Diseases, 2016, 75, 2037-2044.	0.5	29
29	Combined Inhibition of c-Abl and PDGF Receptors for Prevention and Treatment of Murine Sclerodermatous Chronic Graft-versus-Host Disease. American Journal of Pathology, 2012, 181, 1672-1680.	1.9	28
30	Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis. Annals of the Rheumatic Diseases, 2017, 76, 244-251.	0.5	28
31	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. Rheumatology, 2020, 59, 1684-1694.	0.9	27
32	Novel dysfunctional variant inABCG2as a cause of severe tophaceous gout: biochemical, molecular genetics and functional analysis. Rheumatology, 2016, 55, 191-194.	0.9	24
33	Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. Rheumatology, 2015, 54, kev260.	0.9	17
34	Metabolites of type I, II, III, and IV collagen may serve as markers of disease activity in axial spondyloarthritis. Scientific Reports, 2019, 9, 11218.	1.6	15
35	Alterations in activin Aâ€“myostatinâ€“follistatin system associate with disease activity in inflammatory myopathies. Rheumatology, 2020, 59, 2491-2501.	0.9	15
36	Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic. Clinical Rheumatology, 2012, 31, 557-561.	1.0	14

#	Article	IF	Citations
37	Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study. Arthritis Research and Therapy, 2015, 17, 341.	1.6	14
38	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. Rheumatology, 2020, 59, 2016-2023.	0.9	14
39	The Nuclear Receptor Constitutive Androstane Receptor/NR1I3 Enhances the Profibrotic Effects of Transforming Growth Factor Î² and Contributes to the Development of Experimental Dermal Fibrosis. Arthritis and Rheumatology, 2014, 66, 3140-3150.	2.9	13
40	Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit. RMD Open, 2021, 7, e001724.	1.8	12
41	IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis. Frontiers in Immunology, 2021, 12, 745523.	2.2	11
42	Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response. Scientific Reports, 2021, 11, 11525.	1.6	10
43	Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: baseline clinical characteristics and subset differences in a single-centre cohort. BMJ Open, 2019, 9, e024713.	0.8	9
44	The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up. Arthritis Research and Therapy, 2021, 23, 173.	1.6	8
45	An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 539-548.	1.4	8
46	Inflammatory myopathy associated with statins: report of three cases. Modern Rheumatology, 2014, 24, 366-371.	0.9	7
47	Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis. Clinical and Experimental Rheumatology, 2019, 37, 358-366.	0.4	7
48	Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study. Rheumatology International, 2019, 39, 1037-1043.	1.5	6
49	Sexual function in patients with idiopathic inflammatory myopathies: a cross-sectional study. Rheumatology, 2021, 60, 5060-5072.	0.9	6
50	THU0057â€...Inhibition of Heat Shock Protein 90 (Hsp90) Prevents Fibrosis by Targeting Canonical TGF-B Signaling. Annals of the Rheumatic Diseases, 2013, 72, A183.1-A183.	0.5	5
51	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. Biomedicines, 2021, 9, 650.	1.4	5
52	Chemokine and Cytokine Profiles in Patients with Hand Osteoarthritis. Biomolecules, 2021, 11, 4.	1.8	5
53	Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study. Frontiers in Medicine, 2022, 9, .	1.2	5
54	Atherosclerosis and Cardiovascular Risk in Systemic Sclerosis. , 2017, , .		4

#	Article	IF	Citations
55	Elevated tenascin-C serum levels in patients with axial spondyloarthritis. Physiological Research, 2020, 69, 653-660.	0.4	4
56	MyomiRs in cultured muscle cells from patients with idiopathic inflammatory myopathy are modulated by disease but not by 6-month exercise training. Clinical and Experimental Rheumatology, 2022, 40, 346-357.	0.4	4
57	Plasma heat shock protein 90 levels in patients with spondyloarthritis and their relation to structural changes: a cross-sectional study. Biomarkers in Medicine, 2021, 15, 5-13.	0.6	3
58	Female Sexual Dysfunction and Pelvic Floor Muscle Function Associated with Systemic Sclerosis: A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2022, 19, 612.	1.2	3
59	Animal Models of Systemic Sclerosis. , 0, , .		2
60	Role of Heat Shock Protein 90 in Autoimmune Inflammatory Rheumatic Diseases. Heat Shock Proteins, 2019, , 105-121.	0.2	2
61	Altered dynamics of lipid metabolism in muscle cells from patients with idiopathic inflammatory myopathy is ameliorated by 6Âmonths of training. Journal of Physiology, 2021, 599, 207-229.	1.3	2
62	Hsp90 Levels in Idiopathic Inflammatory Myopathies and Their Association With Muscle Involvement and Disease Activity: A Cross-Sectional and Longitudinal Study. Frontiers in Immunology, 2022, 13, 811045.	2.2	2
63	A3.16â€…Serum S100A4 correlates with skin fibrosis, lung involvement and disease activity in systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, A48.1-A48.	0.5	1
64	AB0203â€…S100A4 Serum Levels Correlate with Disease Activity, Skin Fibrosis and Lung Involvement in Systemic Sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 871.1-871.	0.5	1
65	A3.10â€…Plasma levels of heat shock protein 90 correlate with disease activity, lung involvement and skin fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, A35.1-A35.	0.5	1
66	S100A4 is elevated in axial spondyloarthritis: a potential link to disease severity. BMC Rheumatology, 2020, 4, 13.	0.6	1
67	AB0410â€…S100A4 PLASMA LEVELS CORRELATE WITH DISEASE ACTIVITY, SKIN FIBROSIS AND INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS PATIENTS. Annals of the Rheumatic Diseases, 2021, 80, 1233.2-1233.	0.5	1
68	Association of altered lipid profile with disease activity, duration, and glucocorticoid treatment in patients with idiopathic inflammatory myopathies. European Journal of Preventive Cardiology, 2021, 28, .	0.8	1
69	OP0245â€…ANTI-S100A4 MONOCLONAL ANTIBODY TREATMENT AMELIORATES SKIN FIBROSIS IN INFLAMMATORY AND NON-INFLAMMATORY PRE-CLINICAL MODELS OF SYSTEMIC SCLEROSIS. Annals of the Rheumatic Diseases, 2021, 80, 150.1-150.	0.5	1
70	SAT0324â€…SEXUAL HEALTH IN WOMEN AND MEN WITH SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY. Annals of the Rheumatic Diseases, 2020, 79, 1107.2-1108.	0.5	1
71	S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals. Clinical and Experimental Rheumatology, 2019, 37, 338-339.	0.4	1
72	Clusterin is upregulated in serum and muscle tissue in idiopathic inflammatory myopathies and associates with clinical disease activity and cytokine profile. Clinical and Experimental Rheumatology, 2021, 39, 1021-1032.	0.4	1

#	Article	IF	Citations
73	The effect of a 24-week physiotherapy and occupational therapy program in systemic sclerosis: a monocentric controlled study with follow-up. Clinical and Experimental Rheumatology, 0, , .	0.4	1
74	Inflammatory myopathy associated with statins: report of three cases. Modern Rheumatology, 2012, , 1.	0.9	0
75	A8.3â€…Deficit of S100A4 Prevents Joint Destruction and Systemic Bone Loss in hTNFtg Mouse Model. Annals of the Rheumatic Diseases, 2013, 72, A58.1-A58.	0.5	0
76	THU0114â€…The Loss of S100A4 Prevents Joint Destruction and Systemic Bone Loss in hTNFtg Mouse Model. Annals of the Rheumatic Diseases, 2013, 72, A201.1-A201.	0.5	0
77	SAT0025â€…Antifibrotic effects of imatinib mesylate are not superior to selective inhibition of PDGFR by ARRY-768 in preclinical models of dermal fibrosis. Annals of the Rheumatic Diseases, 2013, 71, 479.2-479.	0.5	0
78	OP0227â€…Critical Role of the Adhesion Receptor DNAX Accessory Molecule-1 (DNAM-1) in the Development of Inflammation-Driven Dermal Fibrosis in Mouse Model of Systemic Sclerosis. Annals of the Rheumatic Diseases, 2013, 72, A129.1-A129.	0.5	0
79	OP0016â€…Tribbles homolog 3 mediates the stimulatory effects of tgf-beta on fibroblast activation and dermal fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 71, 57.3-58.	0.5	0
80	THU0055â€…The Nuclear Receptor Vitamin D Receptor Regulates TGF-ÃŸ Signaling and Fibroblast Activation in Systemic Sclerosis. Annals of the Rheumatic Diseases, 2013, 72, A182.2-A182.	0.5	0
81	FRI0435â€…Interleukin-35 is Overexpressed in Systemic Sclerosis and its Serum Levels are Elevated in Early Disease. Annals of the Rheumatic Diseases, 2015, 74, 584.3-585.	0.5	0
82	SAT0456â€…Heat Shock Protein 90 Plasma Levels Correlate with Disease Activity, Lung Involvement and Skin Fibrosis in Systemic Sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 825.3-826.	0.5	0
83	AB0723â€…Correlations Between Angiogenic Factors Microvaculature Changes in Systemic Sclerosis â€“ Data From a Single Center Registry. Annals of the Rheumatic Diseases, 2015, 74, 1140.1-1140.	0.5	0
84	FRI0433â€…Nuclear Receptor NR4A1 as a Checkpoint of Physiological Wound Healing and Fibrosis. Annals of the Rheumatic Diseases, 2015, 74, 584.1-584.	0.5	0
85	A2.5â€…Novel dysfunctional variant in ABCG2 gene is a cause of primary hyperuricemia and gout: biochemical, molecular genetic and functional analysis. Annals of the Rheumatic Diseases, 2015, 74, A17.2-A17.	0.5	0
86	Reports from the 2015 American College of Rheumatology Congress. Journal of Scleroderma and Related Disorders, 2016, 1, 16-20.	1.0	0
87	A9.02â€…Heat shock protein 90 plasma levels correlate with disease activity, skeletal muscle, lung and heart involvement in idiopathic inflammatory myopathies. Annals of the Rheumatic Diseases, 2016, 75, A70.2-A71.	0.5	0
88	OP0047â€…Expression of Heat Shock Protein 90 in Muscle Tissue and Plasma Is Increased in Idiopathic Inflammatory Myopathies and Correlates with Disease Activity, Skeletal Muscle, Heart and Lung Involvement. Annals of the Rheumatic Diseases, 2016, 75, 72.2-72.	0.5	0
89	AB0632â€…Association between Interstitial Pulmonary Involvement and Microvaculature Changes in Systemic Sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 1120.3-1120.	0.5	0
90	08.48â€…Increased body fat but decreased lean body mass and bone mineral density in myositis patients are associated with disease duration, inflammatory status, skeletal muscle involvement and physical activity. , 2017, , .		0

#	Article	IF	Citations
91	08.49â€...Efficacy of an intensive 24-week physiotherapy programme in scleroderma patients â€“ preliminary data from a single-centre controlled study. , 2017, , .		0
92	FRI0399â€...Efficacy of an intensive 24-week physiotherapy programme in patients with systemic sclerosis - preliminary data from a single-center controlled study. , 2017, , .		0
93	SAT0358â€...Decreased body fat, lean body mass and bone mineral density in patients with systemic sclerosis are associated with disease activity and physical activity. , 2017, , .		0
94	Idiopathic inflammatory myopathies â€“ increased expression of heat shock protein-90 in muscle tissue and plasma correlates with disease activity and skeletal muscle involvement. Neuromuscular Disorders, 2017, 27, S157.	0.3	0
95	08.01â€...Heat shock protein 90 is increased in muscle tissue and plasma in idiopathic inflammatory myopathies. , 2017, , .		0
96	08.47â€...Decreased body fat, lean body mass and bone mineral density in scleroderma patients are associated with disease activity and physical activity. , 2017, , .		0
97	AB0671â€...Increased body fat but decreased lean body mass and bone mineral density in patients with idiopathic inflammatory myopathies are associated with disease duration, inflammatory status, skeletal muscle involvement and physical activity. , 2017, , .		0
98	THU0027â€...Clusterin is elevated in serum and muscle tissue in idiopathic inflammatory myopathies and is associated with disease activity. , 2017, , .		0
99	02.39â€...Clusterin is increased in idiopathic inflammatory myopathies and is associated with disease activity. , 2017, , .		0
100	AB0665â€...Association between microvaculature changes and pulmonary involvement in systemic sclerosis: a follow-up study. , 2017, , .		0
101	Nonpharmacological Treatment in Systemic Sclerosis. , 2017, , .		0
102	AB0653â€...Efficacy of an intensive 24-week physiotherapy programme in myositis patients - preliminary data from a single-center controlled study. , 2017, , .		0
103	SAT0383â€...Biomarkers of ecm degradation reflect disease activity in radiographic and non-radiographic spondylarthritis. , 2017, , .		0
104	P095â€...Plasma levels of HSP90 are increased in patients with systemic sclerosis with more severe organ involvement. , 2018, , .		0
105	P099â€...Intensive 24-week physiotherapy programme in patients with idiopathic inflammatory myopathies â€“ preliminary data from a single-centre controlled study. , 2018, , .		0
106	SAT0113â€...Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response. , 2018, , .		0
107	SAT0258â€...SEXUAL HEALTH IMPAIRMENT IN WOMEN WITH SYSTEMIC SCLEROSIS. , 2019, , .		0
108	AB0635â€...POTENTIAL BIOMARKERS OF SKIN CHANGES IN SYSTEMIC SCLEROSIS. , 2019, , .		0

#	Article	IF	Citations
109	P166â€…Impact of disease activity, duration and muscle involvement on changes of body composition in myositis patients. , 2019, , .		0
110	P167â€…Association of changes of body composition in scleroderma patients with disease activity, physical activity and serum levels of inflammatory cytokines. , 2019, , .		0
111	P171â€…Hsp90 in axial spondyloarthritis, psoriatic arthritis and rheumatoid arthritis. , 2019, , .		0
112	P024â€…Disturbed sexual functioning in female patients with idiopathic inflammatory myopathies. , 2019, , .		0
113	P025â€…Disturbed sexual functioning in female patients with systemic sclerosis. , 2019, , .		0
114	P044â€…Effect of specialized 6-month ADL training with subsequent a 6-month follow-up period in patients with myositis â€“ preliminary data. , 2019, , .		0
115	P045â€…Effect of specialized 6-month physical-occupational intervention with subsequent 6-month follow-up period in patients with scleroderma â€“ preliminary data. , 2019, , .		0
116	AB0687â€…EFFECTIVENESS OF SPECIALIZED AND INTENSIVE ADL TRAINING IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES â€“ PRELIMINARY RESULTS OF A ONE-YEAR CONTROLLED STUDY. , 2019, , .		0
117	AB0676â€…BODY COMPOSITION IN MYOSITIS PATIENTS AND THE ASSOCIATION WITH DISEASE SPECIFIC FEATURES, PHYSICAL ACTIVITY AND PLASMA LEVELS OF INFLAMMATORY CYTOKINES. , 2019, , .		0
118	OP0066â€…EFFECTIVENESS OF SPECIALIZED HAND/FACE PHYSICAL-OCCUPATIONAL THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS â€“ PRELIMINARY RESULTS OF A ONE-YEAR CONTROLLED STUDY. , 2019, , .		0
119	AB0660â€…SEXUAL HEALTH IMPAIRMENT IN WOMEN WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. , 2019, , .		0
120	Gastrointestinal Involvement in Systemic Sclerosis: Overview, Neglected Aspects, Malnutrition, Body Composition and Management. , 0, , .		0
121	Atherosclerosis in Rheumatology: Old and New Insights. , 0, , .		0
122	AB0412â€…LIPID PROFILE IN IIM PATIENTS AND ITS ASSOCIATION WITH DISEASE ACTIVITY, DURATION, AND GLUCOCORTICOID TREATMENT. Annals of the Rheumatic Diseases, 2021, 80, 1234.1-1234.	0.5	0
123	Lower serum vitamin D in patients with idiopathic inflammatory myopathies is related to altered lipid metabolism in patientsâ€™ muscle cells. FASEB Journal, 2021, 35, .	0.2	0
124	POS0849â€…SEXUAL FUNCTION IS IMPAIRED IN WOMEN WITH IDIOPATHIC INFLAMMATORY MYOPATHIES COMPARED TO HEALTHY CONTROLS. Annals of the Rheumatic Diseases, 2021, 80, 678.2-679.	0.5	0
125	POS0846â€…SEXUAL FUNCTION IS IMPAIRED IN WOMEN WITH SYSTEMIC SCLEROSIS COMPARED TO HEALTHY CONTROLS. Annals of the Rheumatic Diseases, 2021, 80, 677.1-677.	0.5	0
126	Cardiovascular risk in patients with rheumatic disease and its management. Vnitrni Lekarstvi, 2018, 64, 51-59.	0.1	0

#	Article	IF	Citations
127	SAT0483â€…Female sexual dysfunction in patients with systemic sclerosis. , 2018, , .		0
128	AB0799â€…Alterations of body composition in scleroderma patients are associated with disease activity and physical activity but not with lung involvement. , 2018, , .		0
129	FRI0459â€…Microvaculature changes and angiogenic factors in systemic sclerosis â€“ a single centre study. , 2018, , .		0
130	SAT0493â€…Plasma levels of hsp90 are increased in interstitial lung disease and skin fibrosis in patients with systemic sclerosis. , 2018, , .		0
131	THU0399â€…Female sexual dysfunction in patients with idiopathic inflammatory myopathies. , 2018, , .		0
132	AB0800â€…Changes of body composition in myositis patients are associated with disease duration, inflammatory status, skeletal muscle involvement and physical activity. , 2018, , .		0
133	THU0365â€…INCREASED HSP90 IN MUSCLE TISSUE AND PLASMA ASSOCIATES WITH DISEASE ACTIVITY AND SKELETAL MUSCLE INVOLVEMENT IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. Annals of the Rheumatic Diseases, 2020, 79, 414.1-414.	0.5	0
134	FRI0255â€…BODY COMPOSITION IN SCLERODERMA PATIENTS IS ASSOCIATED WITH DISEASE ACTIVITY, SERUM LEVELS OF INFLAMMATORY CYTOKINES AND PARAMETERS OF NUTRITION AND LIPID METABOLISM. Annals of the Rheumatic Diseases, 2020, 79, 711.3-712.	0.5	0
135	OP0135â€…INHIBITION OF HSP90 REDUCES PROGRESSION OF DERMAL FIBROSIS AND INDUCES REGRESSION OF ESTABLISHED EXPERIMENTAL DERMAL FIBROSIS INDUCED BY BLEOMYCIN. Annals of the Rheumatic Diseases, 2020, 79, 87-88.	0.5	0
136	SAT0627-HPRâ€…SEXUAL QUALITY OF LIFE IN 39 FEMALE PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. Annals of the Rheumatic Diseases, 2020, 79, 1273.2-1274.	0.5	0
137	OP0136â€…THE INFLUENCE OF LONG-TERM EXERCISE AND IN VITRO EXERCISE-MIMICKING STIMULATION ON THE PRODUCTION OF MYOKINES AND CYTOKINES IN MYOTUBES OF PATIENTS WITH CHRONIC IDIOPATHIC INFLAMMATORY MYOPATHIES. Annals of the Rheumatic Diseases, 2020, 79, 88.2-88.	0.5	0
138	OP0138â€…CLUSTERIN ASSOCIATES WITH DISEASE MECHANISMS AND INFLAMMATION IN MYOSITIS PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 89.2-89.	0.5	0
139	THU0358â€…NEGATIVE CHANGES OF BODY COMPOSITION IN MYOSITIS PATIENTS AND THEIR ASSOCIATION WITH DISEASE SPECIFIC CHARACTERISTICS, PHYSICAL ACTIVITY AND NUTRITIONAL STATUS.. Annals of the Rheumatic Diseases, 2020, 79, 410.3-410.	0.5	0
140	FRI0262â€…INCREASED PLASMA LEVELS OF HSP90 ARE ASSOCIATED WITH MORE SEVERE LUNG AND SKIN INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS. Annals of the Rheumatic Diseases, 2020, 79, 715-716.	0.5	0
141	The effect of a 24-week physiotherapy and occupational therapy program in systemic sclerosis: a monocentric controlled study with follow-up.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
142	MyomiRs in cultured muscle cells from patients with idiopathic inflammatory myopathy are modulated by disease but not by 6-month exercise training.. Clinical and Experimental Rheumatology, 2022, 40, 346-357.	0.4	0